Vivos Therapeutics(NASDAQ:VVOS) reported second quarter 2025 results on August 20, 2025, marking a pivotal shift from its legacy dentist-focused model to a direct, patient-centric sleep center ...

Ozempic, chemically known as semaglutide, is now the first approved treatment in Canada for type 2 diabetes and to slow ...